An anti-doping group is keeping a close eye on the use of these obesity and diabetes drugs in elite athletes. Here’s why.

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...

A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 ...

Credit: Getty Images In light of Serena Williams’s endorsement of GLP-1 medications, we interviewed an obesity medicine specialist about the implications of these medications for professional athletes ...

The use of GLP-1 receptor agonists, and particularly liraglutide, was associated with an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) during the first year of ...

GLP-1 drugs are meant to treat metabolic diseases like diabetes and obesity. But as they become more available, some people might choose to use them even if they're not currently overweight. NPR's ...

Share on Pinterest An increasing number of people without diabetes are using GLP-1 agonist drugs for weight loss only. Image credit: MarkHatfield/Getty Images. The last few years have seen a marked ...